Dipeptidyl Peptidase-4 Induces Aortic Valve Calcification by Inhibiting Insulin-Like Growth Factor-1 Signaling in Valvular Interstitial Cells
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: Calcification of the aortic valve leads to increased leaflet stiffness and consequently to the development of calcific aortic valve disease. However, the underlying molecular and cellular mechanisms of calcification remain unclear. Here, we identified that dipeptidyl peptidase-4 (DPP-4, also known as CD26) increases valvular calcification and promotes calcific aortic valve disease progression. Methods: We obtained the aortic valve tissues from humans and murine models (wild-type and endothelial nitric oxide synthase-deficient-mice) and cultured the valvular interstitial cells (VICs) and valvular endothelial cells from the cusps. We induced osteogenic differentiation in the primary cultured VICs and examined the effects of the DPP-4 inhibitor on the osteogenic changes in vitro and aortic valve calcification in endothelial nitric oxide synthase-deficient-mice. We also induced calcific aortic stenosis in male New Zealand rabbits (weight, 2.5–3.0 kg) by a cholesterol-enriched diet+vitamin D2 (25 000 IU, daily). Echocardiography was performed to assess the aortic valve area and the maximal and mean transaortic pressure gradients at baseline and 3-week intervals thereafter. After 12 weeks, we harvested the heart and evaluated the aortic valve tissue using immunohistochemistry. Results: We found that nitric oxide depletion in human valvular endothelial cells activates NF-κB in human VICs. Consequently, the NF-κB promotes DPP-4 expression, which then induces the osteogenic differentiation of VICs by limiting autocrine insulin-like growth factor-1 signaling. The inhibition of DPP-4 enzymatic activity blocked the osteogenic changes in VICs in vitro and reduced the aortic valve calcification in vivo in a mouse model. Sitagliptin administration in a rabbit calcific aortic valve disease model led to significant improvements in the rate of change in aortic valve area, transaortic peak velocity, and maximal and mean pressure gradients over 12 weeks. Immunohistochemistry staining confirmed the therapeutic effect of Sitagliptin in terms of reducing the calcium deposits in the rabbit aortic valve cusps. In rabbits receiving Sitagliptin, the plasma insulin-like growth factor-1 levels were significantly increased, in line with DPP-4 inhibition. Conclusions: DPP-4-dependent insulin-like growth factor-1 inhibition in VICs contributes to aortic valve calcification, suggesting that DPP-4 could serve as a potential therapeutic target to inhibit calcific aortic valve disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644
Freeman, R. V., & Otto, C. M. (2005) · Circulation · doi:10.1161/circulationaha.104.486738 · Cited by 1,006
Rajamannan, N. M., Evans, F. J., Aikawa, E., Grande-Allen, K. J., Demer, L. L., Heistad, D. D., Simmons, C. A., Masters, K. S., Mathieu, P., O'Brien, K. D., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.006767 · Cited by 842
Chan, K. L., Teo, K., Dumesnil, J. G., Ni, A., & Tam, J. (2010) · Circulation · doi:10.1161/circulationaha.109.900027 · Cited by 815
Dweck, M. R., Boon, N. A., & Newby, D. E. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.02.093 · Cited by 692
Aortic-Valve Stenosis — From Patients at Risk to Severe Valve Obstruction
Otto, C. M., & Prendergast, B. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1313875 · Cited by 631
Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
Kamstrup, P. R., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.038 · Cited by 595
Pioglitazone attenuates valvular calcification induced by hypercholesterolemia
Chu, Y., Lund, D. D., Weiss, R. M., Brooks, R. M., Doshi, H., Hajj, G. P., Sigmund, C. D., & Heistad, D. D. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.300794 · Cited by 49
Cited by
Aortic Valve Stenosis: From Basic Mechanisms to Novel Therapeutic Targets
Goody, P. R., Hosen, M. R., Christmann, D., Niepmann, S. T., Zietzer, A., Adam, M., Bönner, F., Zimmer, S., Nickenig, G., & Jansen, F. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313067 · Cited by 331
Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy
Kraler, S., Blaser, M. C., Aikawa, E., Camici, G. G., & Lüscher, T. F. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab757 · Cited by 281
Electrocardiogram screening for aortic valve stenosis using artificial intelligence
Cohen-Shelly, M., Attia, Z. I., Friedman, P. A., Ito, S., Essayagh, B. A., Ko, W.-Y., Murphree, D. H., Michelena, H. I., Enriquez-Sarano, M., Carter, R. E., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab153 · Cited by 252
Lumican promotes calcific aortic valve disease through H3 histone lactylation
Huang, Y., Wang, C., Zhou, T., Xie, F., Liu, Z., Xu, H., Liu, M., Wang, S., Li, L., Chi, Q., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae407 · Cited by 124
Multi-Omics Approaches to Define Calcific Aortic Valve Disease Pathogenesis
Blaser, M. C., Kraler, S., Lüscher, T. F., & Aikawa, E. (2021) · Circulation Research · doi:10.1161/circresaha.120.317979 · Cited by 109
Metadata
- Authors
- Choi, B., Lee, S., Kim, S.-M., Lee, E.-J., Lee, S. R., Kim, D.-H., Jang, J. Y., Kang, S.-W., Lee, K.-U., Chang, E.-J., & Song, J.-K.
- Venue
- Circulation
- Published
- 2017-05-16
- Volume
- 135
- Issue
- 20
- Pages
- 1935-1950
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2586937495
- Cited by
- 117
- References
- 9
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.